Cognitive behavioural therapy for drug-resistant psychosis.
A small controlled trial of cognitive behaviour therapy for drug-resistant psychosis is reported. The study was designed as a pilot study for a future larger and longer randomized controlled trial. The therapy was offered to patients with a diagnosis of schizophrenia or schizo-affective psychosis who presented unremitting positive symptoms. An average of 16 sessions were delivered over a six-month period. The results of this pilot study are promising. Rates of engagement in therapy were high. The treatment group also improved significantly on a number of key symptom measures when compared with the controls. These were reductions in delusional conviction, general symptomatology and depression scores. Future studies should offer therapy over a longer period, targeting social as well as symptom change, and considering factors which will enhance maintenance of improvement.
Garety
P A
PA
Department of Psychology, Institute of Psychiatry, London, UK.
Kuipers
L
L
Fowler
D
D
Chamberlain
F
F
Dunn
G
G
D000203:Activities of Daily Living / Q000523:psychology; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D003702:Delusions / Q000523:psychology / Q000534:rehabilitation; D004351:Drug Resistance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010552:Personality Assessment; D010865:Pilot Projects; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000523:psychology / Q000534:rehabilitation*; D012559:Schizophrenia / Q000534:rehabilitation*; D012565:Schizophrenic Psychology; D012917:Social Adjustment
D014150:Antipsychotic Agents